PT2970383T - Processo de tratamento de fibrose - Google Patents
Processo de tratamento de fibroseInfo
- Publication number
- PT2970383T PT2970383T PT147624357T PT14762435T PT2970383T PT 2970383 T PT2970383 T PT 2970383T PT 147624357 T PT147624357 T PT 147624357T PT 14762435 T PT14762435 T PT 14762435T PT 2970383 T PT2970383 T PT 2970383T
- Authority
- PT
- Portugal
- Prior art keywords
- nutlin
- peptides
- inhibition
- pulmonary fibrosis
- fibrosis
- Prior art date
Links
- BDUHCSBCVGXTJM-WUFINQPMSA-N 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazol-1-yl]-oxomethyl]-2-piperazinone Chemical compound CC(C)OC1=CC(OC)=CC=C1C1=N[C@@H](C=2C=CC(Cl)=CC=2)[C@@H](C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)NCC1 BDUHCSBCVGXTJM-WUFINQPMSA-N 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 208000005069 pulmonary fibrosis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361800117P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2970383T true PT2970383T (pt) | 2021-06-03 |
Family
ID=51537978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT147624357T PT2970383T (pt) | 2013-03-15 | 2014-03-17 | Processo de tratamento de fibrose |
Country Status (12)
Country | Link |
---|---|
US (7) | US9630990B2 (pt) |
EP (2) | EP2970383B1 (pt) |
JP (4) | JP6603207B2 (pt) |
KR (3) | KR102588702B1 (pt) |
CN (3) | CN117679487A (pt) |
AU (3) | AU2014233055B2 (pt) |
CA (1) | CA2904870C (pt) |
DK (1) | DK2970383T3 (pt) |
ES (1) | ES2875853T3 (pt) |
HK (1) | HK1218924A1 (pt) |
PT (1) | PT2970383T (pt) |
WO (1) | WO2014145389A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010211428B2 (en) | 2009-02-03 | 2015-09-03 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising said stem cells. |
EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
PT2970383T (pt) * | 2013-03-15 | 2021-06-03 | Univ Texas | Processo de tratamento de fibrose |
IL311537A (en) | 2014-01-28 | 2024-05-01 | Mayo Found Medical Education & Res | Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
CA2949171A1 (en) | 2014-05-16 | 2015-11-19 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved culture method for organoids |
GB201421092D0 (en) | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
GB201421094D0 (en) | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
JP6866296B2 (ja) * | 2015-02-27 | 2021-04-28 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | ポリペプチド治療及びその使用 |
GB201603569D0 (en) | 2016-03-01 | 2016-04-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved differentiation method |
KR102082285B1 (ko) * | 2017-04-13 | 2020-02-28 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 Nutlin-3α (뉴트린-3α) 및 p53 발현 조절 조성물 또는 방법 |
WO2018190680A1 (ko) * | 2017-04-13 | 2018-10-18 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 뉴트린-3α 및 피53 발현 조절 조성물 또는 방법 |
CN107987128B (zh) | 2017-11-17 | 2019-06-11 | 广东医科大学 | 一种功能多肽及其在制备防治肺纤维化药物中的应用 |
WO2020014652A1 (en) * | 2018-07-13 | 2020-01-16 | New York University | Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same |
BR112021004420A2 (pt) * | 2018-09-10 | 2021-06-01 | Board Of Regents, The University Of Texas System | formulação em pó seco de peptídeos de caveolina-1 e métodos de uso dos mesmos |
CN112739367A (zh) * | 2018-09-10 | 2021-04-30 | 肺疾治疗公司 | Cav-1蛋白的修饰的肽片段及其在纤维化治疗中的用途 |
CN109010798A (zh) * | 2018-09-17 | 2018-12-18 | 中山大学中山眼科中心 | 一种多肽的新用途 |
WO2021135647A1 (zh) * | 2019-12-31 | 2021-07-08 | 厦门大学 | 用于胞内递送分子的多聚化递送系统 |
WO2022217037A1 (en) * | 2021-04-09 | 2022-10-13 | Board Of Regents, The University Of Texas System | Compositions and methods for treatment of chronic lung diseases |
CN116789751B (zh) * | 2023-08-22 | 2023-11-17 | 中国农业大学 | 预防和/或治疗纤维化疾病的多肽及其应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4021387A (en) | 1975-11-19 | 1977-05-03 | President And Fellows Of Harvard College | Eosinophilotactic tetrapeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4816449A (en) | 1984-08-09 | 1989-03-28 | Immunetech Pharmaceuticals | Immunotherapeutic anti-inflammatory peptide agents |
US4613676A (en) * | 1983-11-23 | 1986-09-23 | Ciba-Geigy Corporation | Substituted 5-amino-4-hydroxyvaleryl derivatives |
ZA846192B (en) | 1984-08-09 | 1986-03-26 | Merck Patent Gmbh | Immunotherapeutic polypeptide agents |
US5728680A (en) | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
DK53291D0 (da) * | 1991-03-25 | 1991-03-25 | Carlbiotech Ltd As | Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser |
CA2150371C (en) * | 1992-12-11 | 2002-09-17 | Dov Borovsky | Materials and methods for control of pests |
US5559209A (en) * | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
US20030113271A1 (en) | 1997-01-29 | 2003-06-19 | University Technology Corporation | Formulations for pulmonary delivery |
EP1076091A1 (en) | 1999-08-09 | 2001-02-14 | Universite Catholique De Louvain | Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
US20020077283A1 (en) | 2000-09-08 | 2002-06-20 | Sessa William C. | Caveolin peptides and their use as therapeutics |
EP1353676A4 (en) | 2000-12-29 | 2006-05-31 | Alteon Inc | METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS |
GB0119852D0 (en) | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
KR20060096513A (ko) | 2001-12-18 | 2006-09-11 | 에프. 호프만-라 로슈 아게 | 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도 |
EP1734938B1 (en) | 2004-03-26 | 2012-06-20 | Universita' Degli Studi Di Parma | Insulin highly respirable microparticles |
WO2005116077A2 (en) * | 2004-05-25 | 2005-12-08 | Attenuon, Llc | LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY |
US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
TWI299993B (en) | 2005-12-15 | 2008-08-21 | Dev Center Biotechnology | Aqueous inhalation pharmaceutical composition |
US8058227B2 (en) * | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
JP2010506860A (ja) | 2006-10-19 | 2010-03-04 | アンジオケム,インコーポレーテッド | P−糖タンパク質機能を刺激するための化合物およびその使用 |
AU2008334605B2 (en) | 2007-12-13 | 2013-07-18 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
CN102164887A (zh) * | 2007-12-21 | 2011-08-24 | 法博太科制药有限公司 | 抗纤维化剂的卤代类似物 |
WO2009111625A2 (en) * | 2008-03-05 | 2009-09-11 | Board Of Regents, The University Of Texas System | Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
KR20110051245A (ko) | 2008-09-10 | 2011-05-17 | 제넨테크, 인크. | 안구 혈관신생의 억제 방법 |
GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
WO2011098552A2 (en) | 2010-02-11 | 2011-08-18 | Ablynx Nv | Methods and compositions for the preparation of aerosols |
EP2635686B1 (en) | 2010-11-05 | 2018-03-28 | The Regents of The University of California | Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord |
WO2013184482A1 (en) | 2012-06-04 | 2013-12-12 | Yale University | Method of treating and preventing ocular angiogenesis |
EP2968161A4 (en) | 2013-03-13 | 2016-10-26 | Forest Lab Holdings Ltd | MICRONIZED PHARMACEUTICAL COMPOSITIONS |
PT2970383T (pt) | 2013-03-15 | 2021-06-03 | Univ Texas | Processo de tratamento de fibrose |
PE20160789A1 (es) | 2013-11-04 | 2016-08-17 | Univ Texas | Composiciones y metodos para admistracion de una enzima a las vias respiratorias de un sujeto |
WO2015080980A2 (en) | 2013-11-26 | 2015-06-04 | E&B Technologies Llc | Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators |
EP3074049B1 (en) | 2013-11-26 | 2020-05-06 | Yale University | Novel cell-penetrating compositions and methods using same |
BR112021004420A2 (pt) | 2018-09-10 | 2021-06-01 | Board Of Regents, The University Of Texas System | formulação em pó seco de peptídeos de caveolina-1 e métodos de uso dos mesmos |
CN112739367A (zh) | 2018-09-10 | 2021-04-30 | 肺疾治疗公司 | Cav-1蛋白的修饰的肽片段及其在纤维化治疗中的用途 |
-
2014
- 2014-03-17 PT PT147624357T patent/PT2970383T/pt unknown
- 2014-03-17 JP JP2016503339A patent/JP6603207B2/ja active Active
- 2014-03-17 ES ES14762435T patent/ES2875853T3/es active Active
- 2014-03-17 CN CN202311699535.8A patent/CN117679487A/zh active Pending
- 2014-03-17 EP EP14762435.7A patent/EP2970383B1/en active Active
- 2014-03-17 DK DK14762435.7T patent/DK2970383T3/da active
- 2014-03-17 CN CN201480016012.1A patent/CN105263948B/zh active Active
- 2014-03-17 AU AU2014233055A patent/AU2014233055B2/en active Active
- 2014-03-17 KR KR1020217018508A patent/KR102588702B1/ko active IP Right Grant
- 2014-03-17 US US14/775,895 patent/US9630990B2/en active Active
- 2014-03-17 KR KR1020237034239A patent/KR20230148263A/ko active Application Filing
- 2014-03-17 CN CN201910393777.1A patent/CN110201144B/zh active Active
- 2014-03-17 EP EP21168926.0A patent/EP3929207A1/en active Pending
- 2014-03-17 WO PCT/US2014/030147 patent/WO2014145389A1/en active Application Filing
- 2014-03-17 KR KR1020157025554A patent/KR102268883B1/ko active Application Filing
- 2014-03-17 CA CA2904870A patent/CA2904870C/en active Active
-
2016
- 2016-06-16 HK HK16106966.9A patent/HK1218924A1/zh unknown
-
2017
- 2017-03-10 US US15/455,670 patent/US10377796B2/en active Active
- 2017-10-09 US US15/727,828 patent/US20180086791A1/en not_active Abandoned
-
2018
- 2018-07-12 AU AU2018205157A patent/AU2018205157A1/en not_active Abandoned
- 2018-07-17 JP JP2018134098A patent/JP6975690B2/ja active Active
-
2019
- 2019-12-03 US US16/702,101 patent/US11161875B2/en active Active
-
2020
- 2020-05-15 AU AU2020203192A patent/AU2020203192A1/en not_active Abandoned
-
2021
- 2021-08-05 JP JP2021128989A patent/JP7378833B2/ja active Active
- 2021-10-12 US US17/499,859 patent/US11780879B2/en active Active
-
2022
- 2022-12-02 US US18/061,084 patent/US20230100467A1/en active Pending
-
2023
- 2023-08-15 US US18/450,056 patent/US20240059736A1/en active Pending
- 2023-10-25 JP JP2023183297A patent/JP2023178440A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1218924A1 (zh) | 和肽抑制肺纖維化 | |
HRP20170840T4 (hr) | Supstituirani ksantini i metode njihove uporabe | |
ZA201505966B (en) | Peptides and compositions | |
PL2968100T3 (pl) | Kombinacje amidotiazoli alkilowych i konserwantów | |
EP3040413A4 (en) | LACTOBACILLUS CRISPATUS AND APPLICATION THEREOF | |
HK1221416A1 (zh) | 氧雜雙環庚烷和氧雜雙環庚烯的配製品 | |
PL3058936T3 (pl) | Kompozycja peptydów i jej zastosowania | |
HK1224307A1 (zh) | 原毒素- 變體及其使用方法 | |
HK1222399A1 (zh) | 具有抗衰老功效的肽及其用途 | |
HK1218247A1 (zh) | 益生菌和使用方法 | |
GB201316538D0 (en) | New UK Patent Application in the name of Paul J Gainford Ball curler | |
HK1222389A1 (zh) | 肺病症和其他病症的治療 | |
IL242238B (en) | Synthetic anti-inflammatory peptides and their uses | |
SG11201601263WA (en) | Recombinant microorganisms and methods of use thereof | |
ZA201602304B (en) | Modified anti-inflammatory proteins and method of use | |
GB201308639D0 (en) | Biomarkers and uses of thereof | |
EP3006564A4 (en) | NEW PEPTIDE AND ITS USE | |
IL242818B (en) | Il-1beta-il-1ra chimera and methods of using the same | |
EP2990481A4 (en) | NOVEL RECOMBINANT CELLULASE AND USE THEREOF | |
GB201301640D0 (en) | Methods and peptides | |
TWM475192U (en) | Improved structure of umbrella | |
GB201318284D0 (en) | Construction of surfaces | |
ZA201305839B (en) | Containers and methods of erectiing containers | |
GB201304166D0 (en) | CelebQuiff and Instant Quiff | |
GB201301393D0 (en) | Kiddibidet and pottibidet |